AzTrials
AzTrials

Neovascular Age-related Macular DegenerationNCT04642183

Single In-Clinic Encounter With the Notal Vision Home OCT

An observational study of Neovascular Age-related Macular Degeneration and Intermediate Age Related Macular Degeneration (Disorder), run by Notal Vision Inc. at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

this is a single In-Clinic Encounter With the Notal Vision Home OCT study. The study population will include up to 50 Age-related Macular Degeneration patients diagnosed with wet NV-AMD in at least one eye at the time of enrollment. Read more about this study

Who is it for?
Ages 18 years and older
How many people
70 participants
Where
1 siteUnited States
Study dates
16 Nov 2020to 30 Sep 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population will include up to fifty (50) AMD patients diagnosed with wet NV-AMD in at least one eye at the time of enrollment. All subjects will be enrolled at one (1) site in the United States. Patients must meet all inclusion / exclusion criteria. All enrolled subjects should have at least one eye with active (wet) CNV (SRF and/or IRF) at the time of enrollment.

Who may be able to join

  • Ability to speak, read and understand English.
  • Ability to understand and agree to contents of informed consent either in writing or verbally.
  • Eighteen (18) years of age or older at the time of Informed Consent.
  • AMD patients diagnosed with wet NV-AMD in at least one eye (ie, with SRF, and/or IRF).
  • Fellow eye with NV-AMD (with or without fluid) or intermediate AMD.
  • Best corrected Visual Acuity of 20/320 or better in eyes participating at the study.

Who cannot join

  • Subjects with dilated pupils.
  • Any other retinal disease requiring steroidal or anti-VEGF injections.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Elman Retina Group, PA

    Baltimore, Maryland, 21237

Other trials in United States

About this study

Official title: Evaluation of Repeated, In-Clinic, Self-Imaging by NV-AMD Patients Using the Notal Vision Home OCT

this is a single In-Clinic Encounter With the Notal Vision Home OCT study. The study population will include up to 50 Age-related Macular Degeneration patients diagnosed with wet NV-AMD in at least one eye at the time of enrollment. All enrolled subjects should have at least one eye with active (wet) CNV (SRF and/or IRF) at the time of enrollment. All subjects will be enrolled at 1 site in the United States. in this study patients will be placed in a room with the Notal Vision Home OCT device and following a completion of a self tutorial will perform 3 unsupervised self-scans on each study eye (with a rest of ~5 minutes between self-scans). at the end of the testing sessions, the subject will be asked to complete subject user questionnaire.

Read the detailed description

Office Visit:

At the enrollment Office Visit, the exams will be conducted in the following order:

  1. Patient will be informed concerning the study and sign the Informed Consent Form (ICF) prior to conduct of any study procedures
  2. The following data will be collected for each study subject:
  3. Subject's DOB (if allowed) or age
  4. Gender
  5. Number and type of injections and last injection date
  6. Refraction correction
  7. Snellen BCVA on both eyes on the day of the visit.
  8. Eligible eyes of the subject will be scanned, non-dilated, with a Zeiss Cirrus OCT device 3 times with one (1) acceptable volume scan of each eye being obtained.

Scanning pattern to be used:

  1. Macular cube, 6X6mm, 128 B-scans per volume scan NOTE: Any planned treatment for NV-AMD should be administered after completion of all study-related scans.
  2. Eyes of the subject that meet all screening criteria will be enrolled. NOTE: All enrolled subjects should have at least one eye with active CNV (i.e., with SRF and/or IRF) confirmed by commercial OCT scan(s) at the time of enrollment 7. The following data will be collected for the study eye(s):
  3. Qualifying diagnosis for the study eye from the subject's medical record
  4. From the subject's medical record, the presence of other ophthalmic conditions including but not limited to:
  5. Cataract ii. Glaucoma iii. Dry Eye iv. Other macula findings, e.g., epi retinal membrane, macular hole, vitreo-macular traction (VMT) Following confirmation of subject eligibility, subject will be placed in a room with the NVHO device which has been set up by a clinic technician.
  6. The clinic technician will register the subject using the touchscreen of the NVHO device.
  7. The subject will perform a self-tutorial, without any help from the clinic's staff. The training flow begins with demonstration clips followed by a practice phase. The training flow will be followed by a self-scan that the system uses as a calibration session. Note: If an eye cannot calibrate during 3 separate attempts or fails to test 3 consecutive times, the subject will discontinue self-imaging in this eye. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
  8. Following completion of the training and calibration session, the clinic technician sets the device for testing flows. The subject will perform three (3) unsupervised self-scans on each study eye with a rest period of ~5 minutes between self-scans. In case of scan failures, the user will perform up to 3 additional attempts to complete the required 3 self-scans. The number of attempts will not exceed 3 times per study eye.
  9. At the end of each self-scanning, and during the 5-minute resting period, image results will be automatically uploaded to Notal Health Cloud. NOTE: Support provided by the sponsor will be available to study subjects throughout the study including tutorial, calibration and scanning, if needed.
  10. Once the subject completes the testing session in its entirety, the subject will be asked to complete a questionnaire about their experience as a user of the NVHO device and proposed naming options for the device.
  11. Collect AEs, if applicable.
  12. Exit the subjects from the study.
  13. Self-scan data will be backed up on the NVHO device. Commercial Cirrus OCT data will be copied to an external drive and sent to a Notal repository. Study visit data and subject questionnaires responses will be entered into a Sponsor-provided CRF and sent to a Notal repository.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of subjects who completed self-scanning following a self-tutorial.

    Percentage of subjects who were able to perform a full self-scanning and generate a retinal volume scan.

    Measured: 5-10 minutes

  2. Percentage of eyes that performed 4 self-scans with the same fluid status

    Percentage of eyes that performed 4 self-scans, where their fluid status (fluid present/absent) is identical based both human reader and the Notal OCT Analyzer (NOA) artificial-intelligence (AI) module.

    Measured: About 30 min - upon completion of the study visit

  3. Agreement between the Cirrus OCT and the NVHO device in detecting fluid in the central 3x3mm of the macula.

    Measured: About 30 min - upon completion of the study visit

  4. Summary of subject questionnaire results.

    For the multi-choice questions - the average score (1-5) for each question. For open questions - collect the user's feedback for future improvements of the device

    Measured: 5-10 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Nov 2020
  2. Study start16 Nov 2020
  3. Primary completion24 Aug 2021
  4. Study completion30 Sep 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
70 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04642183
Sponsor's protocol ID
C2020.005
Status last verified
Jun 2021
First submitted
11 Nov 2020
Last updated
23 Dec 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Neovascular Age-related Macular Degeneration and Intermediate Age Related Macular Degeneration (Disorder), run by Notal Vision Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of subjects who completed self-scanning following a self-tutorial. (time frame: 5-10 minutes). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2021; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in